As treatment options for acute myeloid leukemia (AML) evolve, new therapies could change the patient experience around allogeneic stem cell transplant. CURE sat down with Dr. Gwen Nichols, chief ...
The MarketWatch News Department was not involved in the creation of this content. Results from the Precision-T study showed Orca-T significantly improved survival free from chronic GvHD in patients ...
Post hoc data suggest Orca-T may boost survival and cut non-relapse mortality after allogeneic stem cell transplant in MDS and leukemias, pending phase 3 validation.
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The treatment is designed to be ...
New retrospective analysis showed Orca-T with reduced intensity conditioning (RIC) demonstrated favorable OS, RFS and GRFS compared to PTCyCompany announced first patients dosed in the Phase 2 ...
Orca Bio is a late-stage biotechnology company developing high-precision cell therapies for the treatment of blood cancer and autoimmune diseases. The company’s manufacturing platform uses single-cell ...
Results from the Precision-T study showed Orca-T significantly improved survival free from chronic GvHD in patients with AML, ALL and MDS compared to a conventional allogeneic hematopoietic stem cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results